Skip to main content

Table 2 RV volumetric parameters at baseline, 6 and 12 months (mean ± SD) in the 2 treatment arms.

From: Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

   Baseline 6 Months 12 Months p
Deferiprone      
  T2*, ms 13.0 (32) 15.4 (38) 16.5 (38) < 0.001
  RVEDV, mL 122.5 ± 24.9 123.2 ± 26.0 121.3 ± 24.9 0.61
  RVESV, mL 37.7 ± 11.7 35.9 ± 11.7 34.2 ± 11.3 0.009
  RVSV, mL 84.7 ± 16.5 87.3 ± 16.5 87.1 ± 17.0 0.16
  RVEF, % 69.6 ± 5.2 71.4 ± 4.7 72.2 ± 5.3 0.001
Deferoxamine      
  T2*, ms 13.3 (30) 14.4 (37) 15 (39) <0.001
  RVEDV, mL 124.7 ± 27.7 124.4 ± 26.2 128 ± 32.1 0.17
  RVESV, mL 38.1 ± 12.6 37.2 ± 12.5 39.1 ± 13.0 0.38
  RVSV, mL 86.7 ± 18.0 87.0 ± 15.5 88.9 ± 21.3 0.25
  RVEF, % 70.0 ± 5.8 70.8 ± 5.2 69.9 ± 4.6 0.93
  1. The T2* values show the geometric mean and CV. The p value reflects the change from baseline to 12 months.